These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18821474)

  • 1. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
    Fock KM; Ang TL
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 3. Dexlansoprazole MR: a review.
    Hershcovici T; Jha LK; Fass R
    Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C; Desilets AR; Willett K
    Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR; Marzella N
    Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
    Lee JH; Kim MJ; Lee JS; Choe YH
    Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
    Vakily M; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexlansoprazole MR.
    Aslam N; Wright R
    Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL
    Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC; Vakily M; Dixit T; Mulford D
    Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW; Peura DA
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
    Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
    Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
    Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
    Bordin DS; Masharova AA
    Eksp Klin Gastroenterol; 2008; (5):85-90. PubMed ID: 19145922
    [No Abstract]   [Full Text] [Related]  

  • 18. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD; Scott LJ
    Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
    Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.